HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Dyspnea (Shortness of Breath)

Difficult or labored breathing.
Also Known As:
Shortness of Breath; Breath Shortness; Breath Shortnesses; Dyspneas
Networked: 6394 relevant articles (606 outcomes, 461 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Chronic Obstructive Pulmonary Disease (COPD)
2. Fatigue
3. Cough
4. Heart Failure
5. Neoplasms (Cancer)

Experts

1. Mueller, Christian: 30 articles (11/2015 - 02/2004)
2. O'Donnell, Denis E: 27 articles (06/2015 - 08/2002)
3. Januzzi, James L: 24 articles (01/2016 - 12/2004)
4. Bruera, Eduardo: 17 articles (12/2015 - 12/2003)
5. Maisel, Alan S: 17 articles (04/2015 - 02/2002)
6. Peacock, W Frank: 17 articles (04/2014 - 04/2004)
7. Clopton, Paul: 17 articles (06/2013 - 01/2002)
8. Maisel, Alan: 16 articles (11/2015 - 01/2002)
9. Webb, Katherine A: 16 articles (06/2015 - 08/2002)
10. Wu, Alan H B: 16 articles (06/2013 - 07/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Dyspnea:
1. OxygenIBA
2. Brain Natriuretic Peptide (Natrecor)FDA Link
3. tiotropium (Spiriva)FDA Link
4. Opioid Analgesics (Opioids)IBA
5. Albuterol (Salbutamol)FDA LinkGeneric
6. sildenafil (Viagra)FDA Link
01/01/2014 - "Sildenafil 50 mg/day resulted in a remarkable improvement of the dyspnea and Raynauds' with a significant improvement of the skin tightness as the MRSS became 22. "
04/01/2013 - "All patients exhibited improved exercise capacity with an increase of 6MWD from 63 to 268 (average 138.4±40.7) meters, significantly reduced Borg dyspnea score from maximum 9 down to 1 or 0, and reduced WHO functional class of PH from III or IV down to II. These results indicate that STS exhibits remarkable beneficiary effects on treating PH patients either alone or in concert with sildenafil."
07/01/2014 - "J receptor threshold doses were elevated in ES patients and fell significantly with sildenafil therapy that was associated with improved exercise tolerance, implying thereby a role of J receptors in producing dyspnea in ES patients."
12/01/2008 - "As compared to placebo sildenafil showed a significant improvement in 6-min walk test (68.90 (95% CI 31.14 - 106.65), p = 0.0003), mean pulmonary artery pressure (-13.04 (95% CI - 25.94 to -0.15), p = 0.05), mean cardiac index (0.39 (95% CI 0.24 - 0.54), p < 0.00001), mean Borg dyspnea score (-1.23 (95% CI -1.36 to -1.10), p < 0.00001), mean pulmonary vascular resistance (-171 (95% CI -300 to -30.90), p = 0.02), improvement in functional class (6.48 (95% CI 2.74 - 15.33), p < 0.001) and a nonsignificant change in mean right atrial pressure and clinical worsening. "
03/10/2005 - "NYHA class (baseline 3.8 +/- 0.4 vs. 4 weeks 2.4 +/- 0.5, p = 0.002), Borg dyspnea index (8.1 +/- 1.7 vs. 4.4 +/- 1.9, p = 0.0007), 6-min walk distance (234 +/- 44 vs. 377 +/- 128 m, p = 0.001) and Pulmonary artery pressure (125 +/- 15 vs. 113 +/- 18 mm Hg p = 0.05) are significantly improved with sildenafil 50 mg bid at 4 weeks. "
7. Morphine (MS Contin)FDA LinkGeneric
8. Bronchodilator Agents (Bronchodilators)IBA
9. pro-brain natriuretic peptide (1-76)IBA
10. Carbon MonoxideIBA

Therapies and Procedures

1. Aftercare (After-Treatment)
2. Activities of Daily Living (ADL)
3. Drug Therapy (Chemotherapy)
4. Stents
5. Pneumonectomy (Lung Volume Reduction)